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Abstract
Background: Coagulase negative staphylococci (CoNS) are the most common cause of neonatal sepsis in the
Neonatal Intensive Care Unit (NICU). A minority of neonates does not respond to vancomycin therapy and
develops persistent bacteremia, which may be treated with rifampin. We evaluated the use of rifampin in
persistent CoNS bacteremia.
Methods: Retrospective study of 137 neonates with CoNS bacteremia during admission to a tertiary NICU between
July 2006 and July 2009. Main outcome measures were total duration of bacteremia and the adequacy of
vancomycin and rifampin therapy.
Results: 137/1696 (8.0%) neonates developed a CoNS bacteremia. Eighteen were treated with rifampin because of
persistent bacteremia (3 positive blood cultures at least 48 hours apart with clinical symptoms) or (a serious
suspicion of) an intravascular thrombus. Duration of bacteremia prior to rifampin therapy (8.0 ± 3.6 days) was
positively correlated (p < 0.001) to the total duration of bacteremia (10.3 ± 3.7 days). After starting rifampin therapy
C-reactive protein (CRP) levels of all neonates declined and blood cultures became sterile after 2.3 ± 1.6 days.
Vancomycin levels were not consistently measured in all neonates, resulting in late detection of subtherapeutic
trough levels.
Conclusion: Rifampin may be effective in the treatment of persistent CoNS infections in neonates. Outcome may
be improved by adequate monitoring of vancomycin trough levels.
Background
Sepsis due to coagulase negative staphylococci (CoNS) is
common in the neonatal intensive care unit (NICU).
The incidence of CoNS sepsis varies between 1.3 and
19.9%, depending on birth weight and gestational age
[1-5]. Most of these infections respond well to vancomy-
cin, the first drug of choice. A minority of neonates
develops a persistent staphylococcal bacteremia, which
does not respond to vancomycin. For these neonates
rifampin may be a safe and effective additive treatment
to vancomycin [1,6-8]. Interaction between vancomycin
and rifampin in treatment of staphylococcal infections is
ambiguous, as some studies demonstrate antagonism
and others synergism or indifference [9-12]. High con-
centrations of rifampin may result in antagonism
[13,14]. Rifampin is only effective as combination
therapy, because resistance develops when rifampin is
used as monotherapy [15].
Through its highly lipophilic character, rifampin mole-
cules can easily cross biological membranes, resulting in
a wide tissue distribution [6,16]. The efficacy of rifampin
in persistent staphylococcal bacteremia is due to its abil-
ities to enhance serum bactericidal activity and to pene-
trate phagocytic leukocytes for intraleukocytic killing of
staphylococci [17].
Pharmacokinetic research has demonstrated a positive
correlation between the duration of rifampin therapy
and its clearance, the equilibrium clearance is achieved
after one to two weeks. The increase in clearance and
decrease in half-life are probably due to auto-induction
of the metabolism of rifampin and require caution to
maintain serum levels within the therapeutic range by
adjusting the dose of rifampin, when necessary [6,16,18].
Although CoNS bacteremia is common in NICUs and
the treatment of persistent CoNS bacteremia with rifam-
pin seems successful, previous studies were only small
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The aim of this study was to evaluate the existing local
guidelines for the use of rifampin therapy in persistent
CoNS infection, checking the current indications to
start rifampin therapy and estimating its efficacy.
Methods
Study population
The study population of this retrospective chart review
consisted of all neonates admitted to the neonatology
department of the Leiden University Medical Center
(LUMC) between July 2006 and July 2009. The Medical
Ethics Committee of the LUMC did not require
approval of this study because it consisted of retrospec-
tive chart review, nor did the medical ethics committee
require written consent by the parents for their infant’s
information to be stored in the hospital database and
used for research. Approval by the ethics committee and
informed consent was not necessary as the patient data
were analyzed anonymously.
Inclusion criterion was the presence of a positive
blood culture for CoNS. Persistent CoNS bacteremia
was defined as 3 positive blood cultures, spaced at least
48 hours apart, in combination with clinical symptoms
of sepsis. The indication to start rifampin treatment was
persistent CoNS bacteremia despite treatment with van-
comycin and removal of indwelling catheters, or a non-
persistent CoNS bacteremia in combination with a pro-
ven intravascular thrombus. Starting dose of rifampin
was 10 mg/kg/day intravenously.
Data collection
Data on demographic, perinatal and postnatal clinical char-
acteristics were collected to provide an overview of baseline
characteristics and included birth weight, gestational age,
gender, exposure to prenatal and postnatal steroids, pre-
sence of chorioamnionitis, hyperglycemia, prolonged rup-
ture of membranes (PROM), asphyxia, respiratory distress
syndrome (RDS) [19], bronchopulmonary dysplasia (BPD)
[20], necrotizing enterocolitis (NEC) [21], cystic periventri-
cular leukomalacia (PVL) [22] and intraventricular hemor-
rhage (IVH) [23,24]. These data were collected from
the neonatal charts and used to compare neonates with
non-persistent and persistent CoNS bacteremia.
Primary outcome measures were the total duration of
bacteremia and the adequacy of vancomycin treatment,
estimated by following trough levels obtained after the
initiation of vancomycin therapy until the tenth day of
rifampin therapy. The desired range of trough levels of
vancomycin was 5-10 mg/L, trough levels <5 mg/L were
considered to be subtherapeutic and the desired range
for peak levels was 20-30 mg/L. Other variables studied
included plasma urea and creatinine levels and duration
of vancomycin therapy.
Main outcomes for analysis of the group of rifampin
treated neonates were total duration of bacteremia and
rapidity of sterilization of blood cultures after the start
of rifampin. Age at start of infection, CRP levels from
the first day of CoNS positive blood culture until the
tenth day of rifampin treatment, and duration and dose
of rifampin treatment were additional variables among
rifampin treated neonates.
Identification of CoNS isolates was performed by the
microbiology department using Bactec Peds Plus bottles
(Becton and Dickinson, Franklin Lakes, NJ USA). Blood
cultures, complete blood count and CRP were drawn
upon clinical suspicion of sepsis. CRP levels were deter-
mined daily during therapy with antibiotics. Vancomycin
serum samples were drawn just before the third dose
and 1 hour after administration of the third dose. When
the dosage of vancomycin was changed, another serum
sample was drawn around the second dose after the
change. CRP levels were measured using a immunotur-
bidimetric assay (imCRP, detection limit ≥3 mg/L [25])
and serum vancomycin levels by a fluorescence polariza-
tion assay [26].
CoNS bacteremia was an indication for removal of
central venous lines and sonography for a remaining
vascular thrombus.
Statistical analyses
Data are reported as mean values ± standard deviation,
minimum and maximum, numerical values or cate-
gories. Analyses were performed with SPSS Version 16.0
(SPSS Inc., Chicago, IL). Numerical data were analyzed
by bivariate Pearson correlation and unpaired T-tests,
categorical data were analyzed using a chi-squared test.
To correct for potential confounding effects, logistic
regression analysis was done.
Results
In the period between July 2006 and July 2009 1696
neonates were admitted to the NICU with a mean birth
weight of 1271 ± 663 gram and a gestational age of 29.2
± 3.2 weeks. The incidence of CoNS bacteremia was
137/1696 (8%), 17 (12%) of these neonates developed a
persistent CoNS bacteremia and in 3 of them an intra-
vascular thrombus was identified. One neonate with a
CoNS sepsis also had a S. aureus sepsis.
A flowchart of the included patients can be seen in
figure 1. Baseline characteristics of the included patients
are listed in table 1. Newborn infants with persistent
CoNS bacteremia had lower birth weights (p = 0.008)
and, independent of birth weight, more often hypergly-
cemia (p = 0.007), than infants with non-persistent
CoNS bacteremia. Subtherapeutic vancomycin trough
levels were equally divided among the groups with per-
sistent and non-persistent CoNS bacteremia (p = 0.712).
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ment, started after 8.0 ± 3.6 (mean ± SD) days of CoNS
bacteremia. 13/18 neonates had persistent CoNS bacter-
emia (in three of them an intravascular thrombus was
found), 3/18 had an intravascular thrombus with a non-
persistent CoNS bacteremia, 2/18 received rifampin
because of increasing CRP levels during vancomycin
therapy in combination with severe thrombocytopenia
and a serious suspicion of an intravascular thrombus.
Figure 2 shows the course of the CRP levels before
and after the first CoNS positive blood culture, for both
infants treated with and without rifampin (start of
rifampin is marked, dotted lines represent infants with-
out rifampin therapy).
CRP levels from the first day of a CoNS positive blood
culture until the tenth day of rifampin therapy demon-
strate a serious decline in CRP levels after starting
rifampin therapy (figure 3). Indwelling catheters were
removed before the first CoNS positive blood culture
(6 times), on the day of the first CoNS positive blood
culture (3 times) or after the first CoNS blood culture
(6 times, although in all these infants maximum CRP
was achieved after removal of the catheter). The most
important decline in CRP occurred during the first
3 days after the start of rifampin. In these first 3 days
the blood culture of most neonates became sterile, with
a mean duration of 2.3 ± 1.6 days. Values of other infec-
tion- and pharmacokinetic parameters of the neonates
treated with rifampin are listed in table 2.
Before the start of rifampin all neonates received van-
comycin as monotherapy (n = 1) or in combination with
ceftazidim (until definitive identification and antimicro-
bial susceptibility testing of gram-positive cocci in clus-
ters) (n = 17). The duration of vancomycin therapy was
8.9 ± 4.5 days. Ten neonates had adequate initial vanco-
mycin levels, in 8 infants vancomycin dosage had to be
readjusted. Vancomycin trough levels between the first
day of CoNS positive blood culture and the tenth day of
rifampin treatment are presented in figure 4. In contrast
to vancomycin levels, rifampin levels were never
obtained.
The presence of an intravascular thrombus did not
correlate with the total duration of CoNS bacteremia or
with the rapidity of sterilization of blood cultures after
the start of rifampin treatment.
Discussion
Comparing our incidence of CoNS bacteremia (8%) with
other studies is difficult, as the composition of study
populations vary. Most studies report a lower incidence,
probably due to higher birth weights and gestational
ages in these populations [2-4]. One study reported an
incidence of 19.9%, but neonates in this study had a
lower gestational age [5]. Effectiveness of rifampin treat-
ment in persistent staphylococcal bacteremia in neo-
nates has been demonstrated in several case reports and
pharmacokinetic studies, in which speed of sterilization
of the blood culture was the main outcome [1,6-8]. Our
Figure 1 Flow chart of included patients.
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Page 3 of 7Table 1 Baseline characteristics of all included patients
Non-persistent CoNS bacteremia
N = 120
Persistent CoNS bacteremia
N=1 7
P-value
Prenatal Steroids 0.668
0 doses 50 (43.1%) 9 (52.9%)
1 dose 47 (40.5%) 5 (29.4%)
2 doses 19 (16.4%) 3 (17.6%)
Chorioamnionitis* 9 (7.8%) 1 (5.9%) 0.784
PROM** 14 (12.0%) 2 (11.8%) 0.981
Asphyxia*** 7 (5.8%) 0 (0%) 0.307
Gestational age, weeks 29.4 ± 3.3 28.0 ± 2.3 0.093
Birth weight, g 1,327 ± 686 874 ± 204 0.008
Gender (male) 71 (59.2%) 10 (58.8%) 0.979
Multivariate
P-value
(corrected for birth weight)
Hyperglycemia**** 8 (6.7%) 8 (47.1%) 0.007
IVH grade 3/4 9 (7.5%) 0 (0.0%) 0.999
Cystic PVL 2 (1.7%) 1 (5.9%) 0.640
NEC grade 2/3 4 (3.3%) 2 (11.8%) 0.766
RDS grade 3/4 23 (19.2%) 7 (41.2%) 0.788
BPD***** 26 (21.7%) 9 (52.9%) 0.771
Postnatal steroids 7 (5.8%) 4 (23.5%) 0.652
Died during admission 3 (2.5%) 1 (5.9%) 0.754
* Smelly amniotic fluid, maternal fever or signs of infection at birth
** Rupture of membranes >24 hours
*** Presence of minimal 3 criteria:
1) Decelerative CTG or meconium containing amniotic fluid
2) Umbilical cord pH <7.10
3) Apgar score <5 after 5 minutes
4) Spontaneous respiratory depression >5 minutes after birth
5) Multiple organ failure
**** Glucose levels of >10 mmol/L during >12 hours, treated with insulin >12 hours
***** Need for oxygen-therapy at a gestational age of 36 weeks or at discharge
Figure 2 CRP levels (mg/L) from 10 days before positive blood culture until maximum of 10 days after negative blood culture.E a c h
line indicates an individual patient; dotted lines represent infants with persistent CoNS sepsis without rifampin therapy. Start of rifampin therapy
is indicated with circles.
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first days of rifampin treatment. To our knowledge, stu-
dies evaluating the treatment of CoNS bacteremia,
focusing on the adequacy of monitoring and responding
to vancomycin trough levels and the compliance with
starting rifampin after 3 positive blood cultures with an
interval of 48 hours, have not been reported earlier.
This retrospective study has several limitations. The
most important one is the small size of the study popu-
lation (18 patients) available for evaluation of rifampin
treatment. As most neonates with a CoNS bacteremia
respond well to vancomycin, rifampin is given only
incidentally. Another limitation is the absence of an
appropriate control group. As 4 patients with a persis-
tent CoNS bacteremia did not receive rifampin, this
group was too small for comparison purposes. Compari-
son of the occurrence of vancomycin levels below the
therapeutic margin between persistent and non persis-
tent bacteremia appeared difficult, as vancomycin levels
were not regularly assessed in all neonates, especially in
neonates with a non-persistent bacteremia.
Comparing the groups with and without persistent
CoNS bacteremia, significant differences were seen
for birth weight and the presence of hyperglycemia.
Figure 3 CRP levels (mg/L) from the first day of CoNS-positive blood culture until 10
th day after starting rifampin treatment. Each line
indicates an individual patient, the time when indwelling catheters were removed is indicated with a circle.
Table 2 Infection and pharmacokinetic parameters of neonates treated with rifampin
N=1 8 Mean SD Min Max
Age at start of bacteremia 5.4 2.7 1 11
Days of bacteremia before start of rifampin 8.0 3.6 2 14
Days of vancomycin therapy before start of rifampin 8.9 4.5 2 20
Maximum peak level of vancomycin (mg/L) 26.7 3.5 20.0 32.0
Minimum peak level of vancomycin (mg/L) 20.3 4.7 12.8 28.0
Maximum trough level of vancomycin (mg/L) 10.8 2.6 7.3 15.9
Minimum trough level of vancomycin (mg/L) 7.3 3.6 3.5 15.9
CRP at start of rifampin (mg/L) 77.5 44.8 3 146
Maximum CRP during bacteremia (mg/L) 120.3 64.4 9 250
Duration of rifampin therapy (hours) 147.2 52.5 52 264
Dose of rifampin (mg/kg/day) 10.4 3.0 6.0 17.0
Rapidity of sterilization of blood culture after start of rifampin (days) 2.3 1.6 0 6
Total duration of bacteremia (days) 10.3 3.7 4 15
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and resistance, due to high levels of circulating cytokines
and inflammatory markers during sepsis [27]. Persistent
bacteremia may increase the risk for developing co-mor-
bidity such as hyperglycemia.
No clear statements can be made about the possible
influence of adequate monito r i n ga n dt h er e s p o n s et o
vancomycin trough levels on the risk of developing a
persistent CoNS bacteremia. Because vancomycin levels
were not consistently obtained in all neonates (especially
in those without persistent CoNS-bacteremia), an accu-
rate comparison of the occurrence of subtherapeutic
vancomycin trough levels of infants with and without a
persistent CoNS bacteremia was not possible.
Conclusion
Our results suggest that the treatment strategy for per-
sistent staphylococcal bacteremia with rifampin may be
effective, but can be optimized by improving the
monitoring of vancomycin trough levels and minimizing
the delay in starting rifampin treatment. If, in spite of
adequate vancomycin levels, CoNS bacteremia becomes
persistent, rifampin therapy may be started after 6 days
of bacteremia (3 positive blood cultures with a 48 hours
interval after each).
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